TWD
CYTK icon

True Wealth Design’s Cytokinetics CYTK Stock Holding History

True Wealth Design’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45K Sell
17
-1
-6% -$72 ﹤0.01% 1838
2026
Q1 		$1.17K Hold
18
– – ﹤0.01% 1748
2025
Q4 		$1.13K Hold
18
– – ﹤0.01% 1664
2025
Q3 		$973 Buy
+18
New +$742 ﹤0.01% 1757
2025
Q2 		– Sell
-1
Closed -$41 – 2640
2025
Q1 		$41 Buy
+1
New +$46 ﹤0.01% 2432

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

True Wealth Design's CYTK Position: Q2 2026 in Review

True Wealth Design reduced its Cytokinetics (CYTK) stake by 5.6% in Q2 2026, selling an estimated $72 and leaving 17 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1838.

True Wealth Design first reported a position in CYTK in Q1 2025 and has held it in 5 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • True Wealth Design held 17 shares of Cytokinetics worth $1.45K as of Q2 2026.
  • True Wealth Design sold 1 Cytokinetics share in Q2 2026, an estimated $72.
  • Cytokinetics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1838 holding.
  • True Wealth Design first reported a position in Cytokinetics in Q1 2025 and has held it in 5 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.